Hanna Reem, Dalvi Snehal, Bensadoun Rene Jean, Raber-Durlacher Judith E, Benedicenti Stefano
Laser Therapy Centre, Department of Surgical Sciences and Integrated Diagnostics, University of Genoa, Viale Benedetto XV, 6, 16132 Genoa, Italy.
Department of Oral Surgery, Dental Institute, King's College Hospital NHS Foundation Trust, London SE5 9RS, UK.
Pharmaceutics. 2021 Nov 2;13(11):1838. doi: 10.3390/pharmaceutics13111838.
Mitochondrial homeostasis is crucial for energy production and neuronal survival in neurological primary burning mouth syndrome (npBMS). Photobiomodulation therapy (PBMT) has been utilised in npBMS management, however, its role of intervention remains controversial. The aim of this systematic review and meta-analysis of CRD 42020198921 PROSPERO registration reference was to oversee and determine the efficacy of PBMT in patients with npBMS, identifying the gaps and bridge them by proposing recommendations for future studies purposes. PRISMA guidelines and Cochrane Collaboration recommendations followed. Various search engines employed to analyse a total of 351 studies of which 12 were included. A wide range of utilised PBM wavelengths was between 635-980 nm and the power output ranged between 30 mW and 4000 mW. A high risk of bias (RoB) was noted in 7 out of 12 included studies (58.3%), as results of qualitative analysis. Meta-analysis findings of 4 out of 12 studies showed statistically significant intergroup differences (SSID) for visual analogue scale (VAS) values (MD = -1.47; 95% CI = -2.40 to -0.53; Z = 3.07 ( = 0.002) whereas meta-analysis on 5 out of 12 studies revealed SSID for anxiety/depression and quality of life (MD = -1.47; 95% CI = -2.40 to -0.53; Z = 3.07 ( = 0.002), favouring PBMT group to the control treatment strategies. Despite the inconsistency and diversity in PBM parameters (wavelength, power, light source, spot size, emission mode, energy per point, total energy) and treatment protocols (exposure time, number of sessions, time interval between sessions, treatment duration)-majority of the included studies showed positive PBM results. The high RoB and meta-analytical heterogeneity in the eligible studies warrant the necessity to perform well-designed and robust RCTs after acknowledging the drawbacks of the available scientific literature and addressing our suggested recommendations highlighted in our review.
线粒体稳态对于神经原发性灼口综合征(npBMS)中的能量产生和神经元存活至关重要。光生物调节疗法(PBMT)已被用于npBMS的治疗,然而,其干预作用仍存在争议。本系统评价和荟萃分析的目的(CRD 42020198921 PROSPERO注册参考)是监督和确定PBMT对npBMS患者的疗效,找出差距并通过为未来研究提出建议来弥合这些差距。遵循PRISMA指南和Cochrane协作组的建议。使用各种搜索引擎分析了总共351项研究,其中12项被纳入。广泛使用的PBMT波长在635 - 980 nm之间,功率输出在30 mW至4000 mW之间。定性分析结果显示,12项纳入研究中有7项(58.3%)存在高偏倚风险(RoB)。12项研究中的4项荟萃分析结果显示,视觉模拟量表(VAS)值存在统计学显著的组间差异(SSID)(MD = -1.47;95% CI = -2.40至 -0.53;Z = 3.07(P = 0.002)),而12项研究中的5项荟萃分析显示,焦虑/抑郁和生活质量存在SSID(MD = -1.47;95% CI = -2.40至 -0.53;Z = 3.07(P = 0.002)),支持PBMT组优于对照治疗策略。尽管PBMT参数(波长、功率、光源、光斑大小发射模式、每点能量、总能量)和治疗方案(暴露时间、疗程数、疗程之间的时间间隔、治疗持续时间)存在不一致和多样性,但大多数纳入研究显示PBMT结果为阳性。在认识到现有科学文献的缺点并解决我们综述中强调的建议后,合格研究中的高RoB和荟萃分析异质性证明有必要进行设计良好且有力的随机对照试验。